Advances in Management of Pain, Cancer, and Amyotrophic Lateral Sclerosis

  • ID: 4380104
  • Report
  • 15 pages
  • Frost & Sullivan
1 of 3
This edition of the Genetic Technology TOE depicts trends across disease management. Extracellular phosphorilation for pain management, biosimilar therapies for cancer, novel antibodies for immunotherapy, and stem cells for rare diseases are profiled. The corresponding clinical trial analysis is depicted along with industry interactions.

The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Note: Product cover images may vary from those shown
2 of 3
Innovations in Management of Pain, Cancer, and Neurodegeneration
  • Targeting Extracellular Phosphorylation for Pain Management
  • Biosimilar Therapy for Non-squamous Non-small Cell Lung Cancer
  • Novel Bispecific Cancer Immunotherapy
  • Leveraging Mesenchymal Stromal Cells for Treating Amyotrophic Lateral Sclerosis
Clinical Trial Analysis and Industry Interactions
  • Clinical Trial Analysis
  • Clinical Trial Analysis
  • Industry Interactions
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown